Get started
Author

Tanisha Jindal

Observed name: Jindal, Tanisha
ORCID: 0009-0002-0934-868X
Observed ORCID: 0009-0002-0934-868X
OpenAlex ID: A5137196548
Giant Cell Arteritis: Cardiac and Aortic Complications at the Cardio-Rheumatology Interface
2026 · Jay Gohri, Tanisha Jindal, et al. · Journal of Vascular Diseases
ABCL-1703: Aggressive B-Cell Lymphoma Reporting After COVID-19 mRNAVaccination: A Pharmacovigilance Signal in VAERS
2026 · Tanisha Jindal, Jay Gohri, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: ABCL-1703: Aggressive B-Cell Lymphoma Reporting After COVID-19 mRNAVaccination: A Pharmacovigilance Signal in VAERS
2026 · Tanisha Jindal, Jay Gohri, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-1199: Early Platelet Trajectory Stratifies Risk of ICU Transfer and Mortality in Hospitalized Hematologic Malignancy, Independent of Baseline Platelet Count
2026 · Tanisha Jindal, Akshee Batra, et al. · Clinical Lymphoma Myeloma & Leukemia
CT-557: Epstein-Barr Virus–Positive Diffuse Large B-Cell Lymphoma After Heart Transplantation for Anthracycline-Induced Cardiomyopathy in a Childhood Leukemia Survivor
2026 · Jay Gohri, Aryan Maheshwari, et al. · Clinical Lymphoma Myeloma & Leukemia
Comparative Real-World Safety of Bruton Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of Ibrutinib, Acalabrutinib, Zanubrutinib, and Pirtobrutinib
2026 · Tanisha Jindal
Comparative Real-World Safety of Bruton Tyrosine Kinase Inhibitors: A Pharmacovigilance Analysis of Ibrutinib, Acalabrutinib, Zanubrutinib, and Pirtobrutinib
2026 · Tanisha Jindal · Open Science Framework
Insulin autoimmune hypoglycemia unmasking monoclonal gammopathy in type 2 diabetes
2026 · Sai Prasad, Anukriti Sharma, et al. · JCEM Case Reports
Global lung cancer burden attributable to environmental and occupational exposures.
2026 · Akshee Batra, Chinmay Jani, et al. · Journal of Clinical Oncology
PDF
Lactate Clearance and Shock-Stage Refinement in Cardiogenic Shock: A MIMIC-IV Analysis
2026 · Jindal, Tanisha, Krish Ashok Kherajani
Real-world adverse event profile of pirtobrutinib: a disproportionality analysis of the FDA Adverse Event Reporting System, with a focus on cardiovascular safety relative to ibrutinib
2026 · Jindal, Tanisha
Works count: 11
Citation count:
H-index:
I10-index:
Year
Topic
Type